Most Expensive Drugs by NADAC Price
All tracked drugs ranked by highest NADAC (National Average Drug Acquisition Cost) per unit.
What This Ranking Tells Us
The National Average Drug Acquisition Cost (NADAC) reflects the average price pharmacies pay to acquire drugs from wholesalers. Drugs topping this list are typically specialty biologics, oncology medications, or rare disease treatments. High per-unit costs do not always translate to high total treatment costs — some drugs require only a few doses per year while others are taken daily. NADAC excludes rebates and patient assistance programs, so out-of-pocket costs may differ significantly.
Database not yet loaded
Rankings will appear once the database is connected.
Primary source: Centers for Medicare & Medicaid Services (CMS), NADAC Survey. Supplementary labeling: FDA Drug Labels (SPL). These rankings are for informational purposes only and should not be used to make medical decisions.
Frequently Asked Questions
What is NADAC pricing?
NADAC stands for National Average Drug Acquisition Cost. CMS surveys retail pharmacies weekly to determine average costs of acquiring prescription drugs from wholesalers. It represents the actual purchase price pharmacies pay, not the retail price or what patients pay out of pocket.
Why are some drugs so expensive?
The most expensive drugs are typically biologics — complex molecules manufactured from living cells rather than chemical synthesis. Development costs can exceed $1 billion, and manufacturing requires specialized facilities. Patent protection limits generic competition for 12+ years for biologics versus 5-7 years for small-molecule drugs.
Do patients actually pay these prices?
Usually not directly. Insurance negotiations, manufacturer rebates, and patient assistance programs significantly reduce out-of-pocket costs. However, high list prices still affect insurance premiums, deductibles, and co-insurance amounts across the healthcare system.
Reading the Most Expensive Drugs by NADAC Price
This table ranks all tracked drugs by nadac/unit, sourced from Centers for Medicare & Medicaid Services (CMS), NADAC Survey. The dataset is published by the relevant federal agency and updated as new reports and surveys come in. Each row links to a full drug profile so readers can move from headline number to the underlying FDA data — labeling, FAERS reports, recalls, pricing, and shortage status — that explains why a particular drug sits where it does.
The National Average Drug Acquisition Cost (NADAC) reflects the average price pharmacies pay to acquire drugs from wholesalers. Drugs topping this list are typically specialty biologics, oncology medications, or rare disease treatments. High per-unit costs do not always translate to high total treatment costs — some drugs require only a few doses per year while others are taken daily. NADAC excludes rebates and patient assistance programs, so out-of-pocket costs may differ significantly.
Rankings are diagnostic, not prescriptive. Absolute numbers are shaped by exposure volume, reporting practices, and data-collection methodology, so a drug near the top is not automatically "worse" than a drug near the bottom — it may simply be older, more widely prescribed, or manufactured by firms with more visible reporting. Context from Centers for Medicare & Medicaid Services (CMS) updates continuously, which means the relative order here can change from one refresh to the next. Rankings on this page are for educational research only and must not be used as a substitute for medical advice from a licensed clinician.
Explore More Rankings
Read our methodology — how this data is sourced, computed, and verified.